1. Home
  2. UTHR vs CIEN Comparison

UTHR vs CIEN Comparison

Compare UTHR & CIEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • UTHR
  • CIEN
  • Stock Information
  • Founded
  • UTHR 1996
  • CIEN 1992
  • Country
  • UTHR United States
  • CIEN United States
  • Employees
  • UTHR N/A
  • CIEN N/A
  • Industry
  • UTHR Biotechnology: Pharmaceutical Preparations
  • CIEN Telecommunications Equipment
  • Sector
  • UTHR Health Care
  • CIEN Utilities
  • Exchange
  • UTHR Nasdaq
  • CIEN Nasdaq
  • Market Cap
  • UTHR 20.7B
  • CIEN 19.5B
  • IPO Year
  • UTHR 1999
  • CIEN 1997
  • Fundamental
  • Price
  • UTHR $453.53
  • CIEN $188.96
  • Analyst Decision
  • UTHR Buy
  • CIEN Buy
  • Analyst Count
  • UTHR 14
  • CIEN 14
  • Target Price
  • UTHR $471.50
  • CIEN $128.31
  • AVG Volume (30 Days)
  • UTHR 658.6K
  • CIEN 2.4M
  • Earning Date
  • UTHR 10-29-2025
  • CIEN 12-11-2025
  • Dividend Yield
  • UTHR N/A
  • CIEN N/A
  • EPS Growth
  • UTHR 16.08
  • CIEN 3.32
  • EPS
  • UTHR 26.38
  • CIEN 0.98
  • Revenue
  • UTHR $3,128,400,000.00
  • CIEN $4,541,635,000.00
  • Revenue This Year
  • UTHR $13.82
  • CIEN $19.58
  • Revenue Next Year
  • UTHR $5.71
  • CIEN $16.89
  • P/E Ratio
  • UTHR $17.26
  • CIEN $193.21
  • Revenue Growth
  • UTHR 13.50
  • CIEN 12.97
  • 52 Week Low
  • UTHR $266.98
  • CIEN $49.21
  • 52 Week High
  • UTHR $479.50
  • CIEN $193.12
  • Technical
  • Relative Strength Index (RSI)
  • UTHR 62.66
  • CIEN 76.10
  • Support Level
  • UTHR $409.15
  • CIEN $173.80
  • Resistance Level
  • UTHR $479.50
  • CIEN $193.12
  • Average True Range (ATR)
  • UTHR 13.12
  • CIEN 7.40
  • MACD
  • UTHR -1.19
  • CIEN 0.33
  • Stochastic Oscillator
  • UTHR 57.20
  • CIEN 85.87

About UTHR United Therapeutics Corporation

United Therapeutics Corp specializes in drug development for pulmonary arterial hypertension (PAH), a rare and progressive disease marked by abnormally high blood pressure in the arteries of the lungs. The company's therapies for PAH largely focus on the prostacyclin pathway, and many of its treatments are based on the same molecule, treprostinil. The company markets and sells the following commercial therapies in the United States to treat PAH: Tyvaso DPI (treprostinil) Inhalation Powder, Remodulin Injection, Orenitram (treprostinil) Extended-Release Tablets, Adcirca (tadalafil) Tablets, and Unituxin. In addition, it is developing a pipeline of projects that includes new indications and delivery devices for existing products and new products to treat PAH and other conditions.

About CIEN Ciena Corporation

Ciena is a telecommunications equipment provider focused on optical transport technologies, with clients in a number of industries such as communication services providers, web-scale providers, cable operators, government, and large enterprises worldwide. The company provides equipment, software, and services that support transport, switching, aggregation, service delivery, and data traffic management.

Share on Social Networks: